Ventricular Assist Device Market Research Report by Product - Global Forecast to 2025 - Cumulative Impact of COVID-19
Ventricular Assist Device Market Research Report by Product (Biventricular Assist Device, Left Ventricular Assist Device, Right Ventricular Assist Device, and Total Artificial Heart) - Global Forecast to 2025 - Cumulative Impact of COVID-19
May 04, 2021 14:19 ET | Source: ReportLinker ReportLinker Lyon, FRANCE
New York, May 04, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Ventricular Assist Device Market Research Report by Product - Global Forecast to 2025 - Cumulative Impact of COVID-19 - https://www.reportlinker.com/p05911852/?utm source=GNW
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
Share:
New York, May 04, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Ventricular Assist Device Market Research Report by Product - Global Forecast to 2025 - Cumulative Impact of COVID-19 - https://www.reportlinker.com/p05911852/?utm source=GNW
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Ventricular Assist Device Market is expected to grow from USD 1,633.15 Million in 2020 to USD 2,110.46 Million by the end of 2025.
2. The Global Ventricular Assist Device Market is expected to grow from EUR 1,431.97 Million in 2020 to EUR 1,850.49 Million by the end of 2025.
SEATTLE, April 29, 2021, (PHARMIWEB) OverviewOsteoporosis is defined by the micro-architectural degradation of bone tissue, which results in low bone mass and bone fragility, especially in older people. Women are more susceptible to the condition over men, particularly after menopause, when bone loss is increased.
Continuous Positive Airway Pressure Market - Forecast(2021 briefingwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from briefingwire.com Daily Mail and Mail on Sunday newspapers.
Search jobs Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited
Osaka, Japan, April 1, 2021 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the asset transfer associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited (“Teijin Pharma”) for JPY 133.0 billion
®, Liovel
® and Zafatek
®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019. While the products included in the asset transfer continue to play important roles in meeting patient needs in the country, they were outside of Takeda’s chosen business areas – Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience – core to its global long-term growth strategy. The transaction continues Takeda’s strong momentum toward optimizing its portfolio for growth by discovering and delivering life-tran